Literature DB >> 16830793

Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner.

Hsi-Hsien Hsu1, Sue-Fei Cheng, Cheng-Chung Wu, Chun-Hsien Chu, Yi-Jiun Weng, Chung-Sheng Lin, Shin-Da Lee, Hung-Chien Wu, Chih-Yang Huang, Wei-Wen Kuo.   

Abstract

Epidemiologic studies reported that the prevalence of hereditary non-polyposis colon cancer (HNPCC) in male is about 1.5-fold higher than that in female. Decreases in circulatory estradiol (E2) have been reported to downregulate the expression of E2 receptor (ER) and significantly increase the risk of colorectal cancer. Patients that received E2 replacement therapy were found to have a reduction in the incidence of colon adenoma and carcinoma. Furthermore, significant decreases in the expression of ER have been found in colorectal cancer specimens. These data strongly suggest the protective roles of E2 and ER against colorectal cancer. However, the mechanisms remain unexplored. LoVo cells were transient transfected to overexpress ER-beta, DNA fragmentation and caspase activity assay were performed to evaluate apoptotic effects. Western blotting was used to evaluate protein levels, and luciferase activity assay to measure the TNF-alpha promoter activity. Our data clearly demonstrated that E2 and ER-beta alone could upregulate p21 and p27 proteins, which further activate caspase-8 and caspase-9 to induce apoptosis in LoVo cell, and the ER-beta. effects were enhanced by E2. However, overexpressed ER-beta did not influence the expression and promoter activity of TNF-alpha. In addition, E2 and overexpressed ER-beta downregulated the beta-catenin proteins which cause the downregulation of its target genes, cyclin D1 and Rb, to inhibit the cell cycle and cell proliferation. The results indicate that overexpressed ER-beta may induce LoVo cell apoptosis and anti-proliferation by increasing p53 signaling in a ligand-dependent manner, and without hTNF-alpha involvement. Efforts aiming at enhancing ER-beta expression and/or activity may prove to be an attractive alternative therapy against colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830793

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  31 in total

1.  Potential value of estrogen receptor beta expression in colorectal carcinoma: interaction with apoptotic index.

Authors:  Hosam Ghazy Elbanna; Mohamed Awad Ebrahim; Amr Medhat Abbas; Khaled Zalata; Maha Abo Hashim
Journal:  J Gastrointest Cancer       Date:  2012-03

2.  Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon.

Authors:  Soichiro Ishihara; Toshiaki Watanabe; Takuya Akahane; Ryu Shimada; Atsushi Horiuchi; Hajime Shibuya; Tamuro Hayama; Hideki Yamada; Keijiro Nozawa; Keiji Matsuda; Koutarou Maeda; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2011-11-04       Impact factor: 2.571

3.  Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells.

Authors:  Zhenzhen Tu; Yuxiang Ma; Junmei Tian; Hui Li; Walter Akers; Samuel Achilefu; Yueqing Gu
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-08       Impact factor: 4.553

4.  Benefit of primary tumor resection in stage IV colorectal cancer with unresectable metastasis: a multicenter retrospective study using a propensity score analysis.

Authors:  Soichiro Ishihara; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Keisuke Hata; Hioaki Nozawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Kenichi Sugihara; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2015-04-29       Impact factor: 2.571

5.  The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.

Authors:  Ying-En Lee; Hong-Lin He; Yow-Ling Shiue; Sung-Wei Lee; Li-Ching Lin; Ting-Feng Wu; I-Wei Chang; Hao-Hsien Lee; Chien-Feng Li
Journal:  Tumour Biol       Date:  2015-05-01

6.  Phytoestrogens/insoluble fibers and colonic estrogen receptor β: randomized, double-blind, placebo-controlled study.

Authors:  Mariabeatrice Principi; Alfredo Di Leo; Maria Pricci; Maria Principia Scavo; Raffaella Guido; Sabina Tanzi; Domenico Piscitelli; Antonio Pisani; Enzo Ierardi; Maria Cristina Comelli; Michele Barone
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

Review 7.  Oestrogen and colorectal cancer: mechanisms and controversies.

Authors:  Paul A Foster
Journal:  Int J Colorectal Dis       Date:  2013-01-15       Impact factor: 2.571

8.  Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.

Authors:  Samy A F Morad; James P Madigan; Jonathan C Levin; Noha Abdelmageed; Ramin Karimi; Daniel W Rosenberg; Mark Kester; Sriram S Shanmugavelandy; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2013-01-24       Impact factor: 5.858

Review 9.  The p53-estrogen receptor loop in cancer.

Authors:  C Berger; Y Qian; X Chen
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

10.  MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cells.

Authors:  Yu-Jing Fang; Zhi-Zhong Pan; Li-Ren Li; Zhen-Hai Lu; Li-Yi Zhang; De-Sen Wan
Journal:  J Exp Clin Cancer Res       Date:  2009-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.